Rupam Manna, Medical Oncologist, Entrepreneur, interested in Metabolism education and brain science, shared on X:
“Should You Stop a BTK Inhibitor Because the Lymphocyte Count Increased?
A rising lymphocyte count after starting a BTK inhibitor is usually expected—not treatment failure.
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) disrupt CLL cells’ attachment to lymph nodes, causing them to move into the bloodstream.
- Lymph nodes shrink
- Symptoms improve
- Overall disease burden decreases
- Absolute lymphocyte count (ALC) rises transiently
Don’t stop the BTK inhibitor solely because of isolated lymphocytosis if the patient is otherwise responding.
Re-evaluate only if there are enlarging lymph nodes, worsening cytopenias, new B symptoms, or suspicion of Richter transformation.
Remember: Treat the patient, not just the CBC.”
Other articles abot BTK inhibitor on OncoDaily.